T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortinet
FTNT
|
+$2.03B |
| 2 |
Rockwell Automation
ROK
|
+$1.44B |
| 3 |
Autodesk
ADSK
|
+$1.15B |
| 4 |
Citigroup
C
|
+$975M |
| 5 |
ConocoPhillips
COP
|
+$967M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.59B |
| 2 |
GE Aerospace
GE
|
+$1.78B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.38B |
| 4 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 5 |
Philip Morris
PM
|
+$1.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.21% |
| 2 | Healthcare | 15.42% |
| 3 | Financials | 10.99% |
| 4 | Consumer Discretionary | 10.39% |
| 5 | Communication Services | 8.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2676
Horizon Bancorp
HBNC
$1.06B
| $159K | ﹤0.01% |
12,347
+1,749
| +17% | +$22.3K |
|
2677
Aldeyra Therapeutics
ALDX
$92.9M
| $158K | ﹤0.01% |
48,273
+3,446
| +8% | +$11.3K |
|
2678
Altimmune
ALT
$558M
| $156K | ﹤0.01% |
15,238
+1,821
| +14% | +$18.5K |
|
2679
Costamare
CMRE
$1.75B
| $156K | ﹤0.01% |
13,681
+2,223
| +19% | +$24.6K |
|
|
FNA
2680
DELISTED
Paragon 28, Inc.
FNA
| $156K | ﹤0.01% |
12,622
+1,766
| +16% | +$21K |
|
|
TSVT
2681
DELISTED
2seventy bio
TSVT
| $155K | ﹤0.01% |
28,929
+2,893
| +11% | +$13.6K |
|
2682
Stereotaxis
STXS
$137M
| $153K | ﹤0.01% |
58,400
| – | – |
|
|
VINC
2683
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $152K | ﹤0.01% |
1,500
-500
| -25% | -$31.6K |
|
2684
Fulcrum Therapeutics
FULC
$280M
| $151K | ﹤0.01% |
15,900
| – | – |
|
2685
Navitas Semiconductor
NVTS
$3.66B
| $151K | ﹤0.01% |
31,646
+4,533
| +17% | +$26.6K |
|
|
KG
2686
Kestrel Group
KG
$63.5M
| $150K | ﹤0.01% |
3,323
+333
| +11% | +$11.4K |
|
|
SELF
2687
Global Self Storage
SELF
$59.6M
| $149K | ﹤0.01% |
33,399
| – | – |
|
2688
Evolv Technologies
EVLV
$1.03B
| $147K | ﹤0.01% |
32,813
+5,062
| +18% | +$21.9K |
|
|
HTBK
2689
DELISTED
Heritage Commerce
HTBK
| $146K | ﹤0.01% |
16,966
+2,159
| +15% | +$18.8K |
|
2690
OmniAb
OABI
$515M
| $146K | ﹤0.01% |
26,843
+3,108
| +13% | +$17.9K |
|
2691
Lands' End
LE
$390M
| $145K | ﹤0.01% |
13,264
+237
| +2% | +$2.16K |
|
2692
Organogenesis Holdings
ORGO
$229M
| $145K | ﹤0.01% |
50,951
+5,359
| +12% | +$18.2K |
|
2693
Karyopharm Therapeutics
KPTI
$44.4M
| $144K | ﹤0.01% |
6,339
+531
| +9% | +$9.31K |
|
2694
XBiotech
XBIT
$71.3M
| $144K | ﹤0.01% |
17,600
| – | – |
|
2695
Alpha Pro Tech
APT
$55.3M
| $143K | ﹤0.01% |
22,900
| – | – |
|
|
FPI
2696
Farmland Partners
FPI
$427M
| $143K | ﹤0.01% |
12,855
+1,286
| +11% | +$14.5K |
|
2697
SmartRent
SMRT
$274M
| $143K | ﹤0.01% |
53,177
+8,169
| +18% | +$23.6K |
|
2698
Personalis
PSNL
$1.52B
| $142K | ﹤0.01% |
95,000
+34,900
| +58% | +$54.1K |
|
2699
Unisys
UIS
$208M
| $142K | ﹤0.01% |
28,861
-15,206
| -35% | -$92.4K |
|
|
NAPA
2700
DELISTED
The Duckhorn Portfolio, Inc.
NAPA
| $142K | ﹤0.01% |
15,216
+4,170
| +38% | +$38.2K |
|
Similar funds
T. Rowe Price Associates's Q1 2024 Portfolio in Review
As of Q1 2024, T. Rowe Price Associates held 3,021 positions worth $816B, up 9.6% from $744B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q1 2024 filing shows 108 new, 1,941 increased, 738 reduced and 64 closed positions. Its largest new stake was GE Vernova: 2,687,194 shares worth $367M. The largest sale was NVIDIA, an estimated $2.59B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 31% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q1 2024 buy was GE Vernova: 2,687,194 shares worth $367M.
- T. Rowe Price Associates added most to Fortinet in Q1 2024, an estimated $2.03B increase.
- T. Rowe Price Associates's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $2.59B.
- T. Rowe Price Associates fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $621M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $816B portfolio in Q1 2024.
- T. Rowe Price Associates opened 108 new positions and closed 64 in Q1 2024.
- T. Rowe Price Associates's portfolio value rose 9.6% quarter-over-quarter to $816B.
Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.